Enliven Therapeutics’ (ELVN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research report report published on Tuesday, Benzinga reports. HC Wainwright currently has a $37.00 price objective on the stock.

A number of other equities research analysts have also recently issued reports on ELVN. Robert W. Baird initiated coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They set an outperform rating and a $32.00 price objective for the company. Baird R W raised shares of Enliven Therapeutics to a strong-buy rating in a research report on Tuesday, June 11th.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $25.51 on Tuesday. The company has a fifty day moving average price of $23.20 and a two-hundred day moving average price of $21.86. Enliven Therapeutics has a one year low of $9.80 and a one year high of $27.67. The stock has a market cap of $1.20 billion, a P/E ratio of -13.22 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. As a group, equities research analysts anticipate that Enliven Therapeutics will post -1.98 EPS for the current fiscal year.

Insider Buying and Selling

In other Enliven Therapeutics news, COO Anish Patel sold 30,978 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $25.05, for a total transaction of $775,998.90. Following the sale, the chief operating officer now directly owns 345,574 shares in the company, valued at $8,656,628.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, COO Anish Patel sold 30,978 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $25.05, for a total transaction of $775,998.90. Following the completion of the transaction, the chief operating officer now owns 345,574 shares of the company’s stock, valued at approximately $8,656,628.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Benjamin Hohl sold 2,000 shares of the firm’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $25.33, for a total value of $50,660.00. The disclosure for this sale can be found here. Insiders have sold 127,376 shares of company stock valued at $3,169,342 over the last 90 days. 29.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its position in Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Enliven Therapeutics during the first quarter worth $167,000. Baker BROS. Advisors LP bought a new position in shares of Enliven Therapeutics in the 1st quarter valued at $2,020,000. Blackstone Inc. acquired a new stake in shares of Enliven Therapeutics during the 1st quarter valued at $443,000. Finally, Janus Henderson Group PLC grew its position in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after acquiring an additional 305,397 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.